About Horizon Discovery


Articles Posted by Horizon Discovery

Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening

Published: March 27 2018

·         First-to-market Edit-R CRISPRa arrayed crRNA libraries enable native gene overexpression for high-throughput gain-of-function screening ·      

Horizon Discovery enters into agreement with Roche Diagnostics to support the development of immunohistochemistry assays for oncology

Published: December 18 2017

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces that it has entered into an agreement with Roche Diagnostics to assist in

Horizon Discovery introduces Multiplex cfDNA Reference Standard for EGFR mutations to support liquid biopsy assays

Published: December 5 2017

  Horizon Discovery (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces the launch of its new cell line-derived epidermal growth factor receptor

Horizon: 5-Fusion Multiplex FFPE RNA Reference Standard

Published: December 1 2017

The 5-Fusion Multiplex FFPE RNA Reference Standard from Horizon Discovery is a highly-characterized, biologically-relevant quality control material used to assess the performance of targeted NGS, RT-PCR and RT-qPCR assays aimed

Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation

Published: November 15 2017

Horizon Discovery (LSE: HZD) (“Horizon” or the “Company”), a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPRa) from its

Horizon Discovery partners with The Michael J. Fox Foundation to introduce novel pre-clinical models for Parkinson’s Disease

Published: November 2 2017

Horizon Discovery (LSE: HZD) (“Horizon”), a global leader in gene editing and gene modulation technologies, in partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF), today introduced two new gene knock-out

Horizon Discovery introduces OncoSpan, the world’s largest DNA multiplex Reference Standard for oncology

Published: September 26 2017

Horizon Discovery (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announces the launch of OncoSpan, a novel cell line-derived multiplex DNA Reference Standard

Horizon Discovery announces release of high quality, well annotated CHO genome sequence to drive innovation in bioproduction

Published: August 8 2017

 Genome sequence is based on Horizon’s Glutamine Synthetase (GS) Knock-Out CHO K1 manufacturing-ready cell line Sequenced in collaboration with the Wellcome Trust Sanger Institute, this high value reference tool enables the industry

ATUM and Horizon Discovery Announce Collaboration and Technology Cross-License to Simplify and Speed Bioproduction Cell Line Development

Published: June 1 2017

·         Horizon’s CHO SOURCE Platform now incorporates exclusive ATUM vectors as standard ·         ATUM has licensed Horizon’s

Horizon Discovery introduces four BRAF resistant melanoma PDX models

Published: May 26 2017

PDX models of tumors offer better in vivo insights for cancer research and drug development Highly characterized models, originally exclusively licensed from The Wistar Insitute   Horizon Discovery Group plc (LSE: HZD) ("

Horizon Discovery Launches Multiplex I cfDNA Reference Standard Set in Synthetic Plasma

Published: February 21 2017

New format directly addresses DNA extraction, one of the key sources of variability in cfDNA assays  Reference standard provides control throughout entire molecular assay workflow   Horizon Discovery Group, the world leader

Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research

Published: January 16 2017

Access to CRISPR for the generation of GMP biomanufacturing cell lines through extension of existing ERS Genomics license £523,000 provided to Horizon through Innovate UK grant for the development of an automated gene editing

Horizon Discovery Group plc Launches HDx RNA Fusion Reference Standards

Published: March 30 2016

Horizon Discovery Group plc, the leading international gene editing company supplying tools and services that power genomics research and the development of personalized medicines today announces the launch of HDx™ FFPE RNA Fusion Reference

ArcherDX Launches SureShot Triple Fusion-Positive NGS Control

Published: January 12 2016

FFPE reference control developed in collaboration with Horizon Discovery for use alongside Archer FusionPlex™ Panels

Horizon Discovery introduces Cell Free DNA HDx Reference Standards

Published: November 5 2015

Horizon’s new Reference Standards support the development and optimization of cell-free DNA based assays Cell-free DNA analysis is emerging as an important tool for non-invasive liquid biopsies

Horizon Discovery Group plc Introduces Range of Immunohistochemistry HDx Reference Standards

Published: May 6 2015

Horizon’s diagnostics division provides consistent and reproducible reference standards for IHC assays

Horizon Discovery Group plc and Desktop Genetics Launch gUIDEbook Bioinformatics Software for CRISPR Gene Editing

Published: March 16 2015

Software provides simple but powerful solution for designing CRISPR experiments   Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, today

Horizon Discovery Launches GENASSIST Line of Kits and Reagents for Gene-Editing, utilizing CRISPR Technology

Published: February 10 2014

New CRISPR-ready cell line kit and validated RNA guide service to enable easier, robust implementation of gene editing experiments                  Horizon